Open Access
| Issue |
BIO Web Conf.
Volume 237, 2026
2026 8th International Conference on Biotechnology and Biomedicine (ICBB 2026)
|
|
|---|---|---|
| Article Number | 02017 | |
| Number of page(s) | 6 | |
| Section | Pharmacology, Natural Products and Drug Delivery | |
| DOI | https://doi.org/10.1051/bioconf/202623702017 | |
| Published online | 10 June 2026 | |
- M. Abavisani, E. Fazeli, N. Ebadpour, S. Karav, P. Kesharwani, and A. Sahebkar, “The road less traveled: Unexplored targets in the quest for antibiotics against pseudomonas aeruginosa,” Biotechnology Advances, p. 108621, 2025. [Google Scholar]
- H. Wang, F. Song, J. Feng, X. Qi, L. Ma, L. Xie, W. Shi, and Q. Zhou, “Tannin coordinated nanozyme composite-based hybrid hydrogel eye drops for prophylactic treatment of multidrug-resistant pseudomonas aeruginosa keratitis,” Journal of Nanobiotechnology, vol. 20, no. 1, p. 445, 2022. [Google Scholar]
- R. Le Guern, T. Grandjean, S. Stabler, M. Bauduin, P. Gosset, ´E. Kipnis, and R. Dessein, “Gut colonisation with multidrug-resistant klebsiella pneumoniae worsens pseudomonas aeruginosa lung infection,” Nature Communications, vol. 14, no. 1, p. 78, 2023. [Google Scholar]
- R. Dessein, M. Bauduin, T. Grandjean, R. Le Guern, M. Figeac, D. Beury, K. Faure, C. Faveeuw, B. Guery, P. Gosset et al., “Antibioticrelated gut dysbiosis induces lung immunodepression and worsens lung infection in mice,” Critical care, vol. 24, no. 1, p. 611, 2020. [Google Scholar]
- M. J. Gerritzen, D. E. Martens, R. H. Wijffels, L. van der Pol, and M. Stork, “Bioengineering bacterial outer membrane vesicles as vaccine platform,” Biotechnology advances, vol. 35, no. 5, pp. 565–574, 2017. [Google Scholar]
- L. Stejskal, A. Thistlethwaite, F. Ramirez-Bencomo, S. Rashmi, O. Harrison, I. M. Feavers, M. C. Maiden, A. Jerse, G. Barnes, O. Chirro et al., “Profiling igg and iga antibody responses during vaccination and infection in a high-risk gonorrhoea population,” Nature Communications, vol. 15, no. 1, p. 6712, 2024. [Google Scholar]
- S. T. Schetters, W. S. Jong, S. K. Horrevorts, L. J. Kruijssen, S. Engels, D. Stolk, M. H. Daleke-Schermerhorn, J. Garcia-Vallejo, D. Houben, W. W. Unger et al., “Outer membrane vesicles engineered to express membrane-bound antigen program dendritic cells for cross-presentation to cd8+ t cells,” Acta Biomaterialia, vol. 91, pp. 248–257, 2019. [Google Scholar]
- M. Yu, S. Hu, B. Tang, H. Yang, and D. Sun, “Engineering escherichia coli nissle 1917 as a microbial chassis for therapeutic and industrial applications,” Biotechnology Advances, vol. 67, p. 108202, 2023. [Google Scholar]
- J. Li, M. Sun, L. Liu, W. Yang, A. Sun, J. Yu, D. Liu, W. Zhao, M. Cheng, Z. He et al., “Nanoprobiotics for remolding the proinflammatory microenvironment and microbiome in the treatment of colitis,” Nano Letters, vol. 23, no. 18, pp. 8593–8601, 2023. [Google Scholar]
- Y. Wang, A. Dong, J. Man, H. Chen, W. Shen, L. Wang, H. Yang, L. Hu, and K. Yang, “Trem2 scfv- engineering escherichia coli displaying modulation of macrophages to boost cancer radio- immunotherapy,” Advanced Materials, vol. 37, no. 19, p. 2417920, 2025. [Google Scholar]
- L. Huang, W. Tang, L. He, M. Li, X. Lin, A. Hu, X. Huang, Z. Wu, Z. Wu, S. Chen et al., “Engineered probiotic escherichia coli elicits immediate and long-term protection against influenza a virus in mice,” Nature Communications, vol. 15, no. 1, p. 6802, 2024. [Google Scholar]
- P. Van der Ley and V. E. Schijns, “Outer membrane vesicle-based intranasal vaccines,” Current Opinion in Immunology, vol. 84, p. 102376, 2023. [Google Scholar]
- X. Gong, S. Liu, B. Xia, Y. Wan, S. Zhang, B. Zhang, Z. Wang, J. Chen, F. Xiao, X.-J. Liang et al., “Oral delivery of therapeutic proteins by engineered bacterial type zero secretion system,” Nature Communications, vol. 16, no. 1, p. 1862, 2025. [Google Scholar]
- C. Gao, F. Yang, Y. Wang, Y. Liao, J. Zhang, H. Zeng, Q. Zou, and J. Gu, “Vaccination with a recombinant oprl fragment induces a th17 response and confers serotype-independent protection against pseudomonas aeruginosa infection in mice,” Clinical Immunology, vol. 183, pp. 354–363, 2017. [Google Scholar]
- S. O. Ali, X. Q. Yu, G. J. Robbie, Y. Wu, K. Shoemaker, L. Yu, A. DiGiandomenico, A. E. Keller, C. Anude, M. Hernandez-Illas et al., “Phase 1 study of medi3902, an investigational anti– pseudomonas aeruginosa pcrv and psl bispecific human monoclonal antibody, in healthy adults,” Clinical microbiology and infection, vol. 25, no. 5, pp. 629–e1, 2019. [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.